Welcome to our dedicated page for Johnson & Johnson SEC filings (Ticker: JNJ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Johnson & Johnson filings document the regulatory record for a New Jersey healthcare company with Innovative Medicine and MedTech operations. Recent 8-K reports cover sales and earnings releases, dividend actions, annual meeting voting results and other material corporate events.
The company’s proxy materials describe board elections, executive compensation votes and shareholder governance matters. Its exchange-registered securities include JNJ common stock and multiple NYSE-listed notes with maturities extending across the company’s long-term debt profile.
Johnson & Johnson executive Kristen Mulholland, EVP and Chief HR Officer, reported routine equity activity involving stock options and common shares. On February 6, 2026, 5,625 employee stock options with a $101.87 exercise price were automatically exercised immediately before expiration, creating 5,625 shares of common stock.
To cover the option exercise price and related taxes, 3,335 common shares were withheld at a reference price of $239.99. After these transactions, Mulholland directly owned 16,409 shares of Johnson & Johnson common stock. The filing characterizes the option exercise as an automatic event tied to the option’s expiration.
Johnson & Johnson EVP and Chief TO and Risk Officer Kathryn E. Wengel reported an automatic exercise of employee stock options and related share withholding. On February 6, 2026, she exercised 38,945 employee stock options at $101.87 per share, receiving the same number of common shares.
To cover the option exercise price and taxes, 27,270 common shares were withheld at a value of $239.99 per share. After these transactions, she directly held 105,955.8735 Johnson & Johnson common shares, plus 281 shares held indirectly through an ESOP and 86 shares through a 401(k), both as of the plan reporting date.
Johnson & Johnson EVP and Chief Legal Officer Elizabeth Forminard reported an option exercise and related share sale. On 02/05/2026, she exercised employee stock options for 8,921 shares of common stock at $129.51 per share.
On the same date, 6,226 common shares coded "F" were sold in market trades at a weighted average price of $237.90, executed in multiple trades between $237.89 and $237.935. After these transactions, she directly held 15,548 shares of Johnson & Johnson common stock.
A shareholder in Johnson & Johnson has filed a notice of proposed sale under Rule 144 for 6,226 shares of common stock. The shares are to be sold through Fidelity Brokerage Services LLC on the NYSE, with an indicated aggregate market value of $1,481,195.27.
The seller acquired these shares on 02/05/2026 by exercising a stock option that was originally granted on 02/12/2018, paying the exercise price in cash. The issuer reports 2,409,295,102 shares outstanding, providing context for the size of this planned sale.
The Vanguard Group reports beneficial ownership of 243,455,135 shares of Johnson & Johnson common stock, representing 10.1% of the class as of 01/30/2026.
Vanguard has no sole voting or dispositive power. It has shared voting power over 24,005,159 shares and shared dispositive power over all 243,455,135 shares. The shares are held for clients, who are entitled to dividends and sale proceeds, with no single client holding more than 5% of the class.
Vanguard states the position is held in the ordinary course of business and not to change or influence control of Johnson & Johnson. Following an internal realignment on 01/12/2026, certain Vanguard subsidiaries or business divisions may report beneficial ownership separately while pursuing the same investment strategies as before.
Johnson & Johnson CEO Joaquin Duato reported indirect stock sales by his spouse. On January 26, 2026, the spouse sold 51,218 Johnson & Johnson common shares at a weighted average price of $220.986 per share in multiple trades, and another 48,782 shares at a weighted average price of $221.484 per share.
After these transactions, the filing shows the spouse indirectly holding 79,634 shares and 30,852 shares in two accounts. Joaquin Duato is also shown as directly holding 275,967 common shares and 988 shares through a 401(k) plan as of the plan’s most recent reporting date.
A holder of JNJ common stock filed a notice of proposed sale of 100,000 shares under Rule 144. The shares are to be sold through J.P. Morgan Securities LLC on the NYSE, with an aggregate market value of $22,014,000 based on the figures in the notice. As context, the filing lists 2,409,295,102 JNJ common shares outstanding. The planned sale date is approximately 01/26/2026.
The 100,000 shares of common stock were acquired on 03/18/2025 via a transfer from Joaquin Duoto, who originally received the shares as compensation between 02/12/2021 and 02/13/2023. The form also includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Johnson & Johnson filed a Form 8-K to share that it has issued a press release announcing its sales and earnings for the fourth quarter and full year ended December 28, 2025. The filing states that the press release is attached as Exhibit 99.1 and covers both quarterly and annual performance.
The company also attached unaudited comparative supplementary sales data and a condensed consolidated statement of earnings for the same periods as Exhibit 99.2. This 8-K centers on making these earnings materials publicly available rather than detailing the specific financial results within the form itself.
Johnson & Johnson, together with its subsidiary Johnson & Johnson Innovation – JJDC, Inc., reports beneficial ownership of 4,024,861 shares of CVRx, Inc. common stock, representing 15.4% of the class as of the measurement date. JJDC directly owns the shares, and Johnson & Johnson may be deemed to indirectly own them through its wholly owned subsidiary.
The ownership percentage is calculated against 26,210,109 CVRx common shares outstanding as of October 30, 2025, with the ownership position reported as of December 31, 2025. All voting and dispositive power over these shares is reported as shared rather than sole.
Johnson & Johnson, as a reporting person and director of CVRx, Inc., filed an amended Form 4 to correct an earlier insider transaction report. Through its wholly owned subsidiary Johnson & Johnson Innovation - JJDC, Inc., it sold 16,000 shares of CVRx common stock on 11/25/2025 at a weighted average price of $10.03, and 6,337 shares on 11/26/2025 at a weighted average price of $10.03. The shares on 11/25/2025 were sold in multiple trades between $10.00 and $10.22, and on 11/26/2025 between $10.00 and $10.23. After these sales, 4,024,861 CVRx shares were reported as indirectly beneficially owned by Johnson & Johnson through JJDC. The amendment states the 11/25/2025 sale was omitted from the original filing due to an administrative oversight.